Moreover, a significant number of HER2-mutated and ERBB3-mutated samples associated with MSI have been found in metastatic colorectal cancer, theorizing the possibility of combining immunotherapy with anti-HER2 agents for these patients [61]. Here, ERBB3 is linked to metastatic colorectal cancer.